Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2015

01-06-2015 | Urologic Oncology

Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors

Authors: Matteo Santoni, MD, Alessandro Conti, MD, Stefano Partelli, MD, Camillo Porta, MD, Cora N. Sternberg, MD, PhD, Giuseppe Procopio, MD, Sergio Bracarda, MD, Umberto Basso, MD, Ugo De Giorgi, MD, Lisa Derosa, MD, Mimma Rizzo, MD, Cinzia Ortega, MD, Francesco Massari, MD, Roberto Iacovelli, MD, Michele Milella, MD, Giuseppe Di Lorenzo, MD, Sebastiano Buti, MD, Linda Cerbone, MD, Luciano Burattini, MD, Rodolfo Montironi, MD, PhD, Daniele Santini, MD, PhD, Massimo Falconi, MD, PhD, Stefano Cascinu, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2015

Login to get access

Abstract

Background

The aim of this study was to compare survival of resected and unresected patients in a large cohort of patients with metastases to the pancreas from renal cell carcinoma (PM-RCC).

Methods

Data from 16 Italian centers involved in the treatment of metastatic RCC were retrospectively collected. The Kaplan–Meier and log-rank test methods were used to evaluate overall survival (OS). Clinical variables considered were sex, age, concomitant metastasis to other sites, surgical resection of PM-RCC, and time to PM-RCC occurrence.

Results

Overall, 103 consecutive patients with radically resected primary tumors were enrolled in the analysis. PM-RCCs were synchronous in only three patients (3 %). In 56 patients (54 %), the pancreas was the only metastatic site, whereas in the other 47 patients, lung (57 %), lymph nodes (28 %), and liver (21 %) were the most common concomitant metastatic sites. Median time for PM-RCC occurrence was 9.6 years (range 0–24 years) after nephrectomy. Surgical resection of PM-RCC was performed in 44 patients (median OS 103 months), while 59 patients were treated with tyrosine kinase inhibitors (TKIs; median OS 86 months) (p = 0.201). At multivariate analysis, Memorial Sloan Kettering Cancer Center risk group was the only independent prognostic factor. None of the other clinical variables, such as age, sex, pancreatic surgery, or the presence of concomitant metastases, were significantly associated with outcome in PM-RCC patients.

Conclusions

The presence of PM-RCC is associated with a long survival, and surgical resection does not improve survival in comparison with TKI therapy. However, surgical resection leads to a percentage of disease-free PM-RCC patients.
Literature
1.
Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008;15:3954–66.PubMed
2.
3.
Kassabinn A, Stein J, Jabbour N, et al. Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology. 2000;56:211–5.CrossRef
4.
Shah S, Mortele KJ. Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, magnetic resonance imaging features. Semin Ultrasound CT MR. 2007;28:357–70.CrossRefPubMed
5.
Bassi C, Butturini G, Falconi M, Sargenti M, Mantovani W, Pederzoli P. High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg. 2003;90:555–9.CrossRefPubMed
6.
Wente MN, Kleeff J, Esposito I, Hartel M, et al. Renal cancer cell metastasis into the pancreas. Pancreas. 2005;30:218–22.CrossRefPubMed
7.
Ballarin R, Spaggiari M, Cautero N, et al. Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol. 2011;17:4747–56.CrossRefPubMedCentralPubMed
8.
Medioni J, Choueiri TK, Zinzindohouè F, et al. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol. 2009;181:2470–5.CrossRefPubMed
9.
Grassi P, Verzoni E, Mariani L, et al. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer. 2013;11:484–8.CrossRefPubMed
10.
Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40.PubMed
11.
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873–90.CrossRefPubMed
12.
Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:512–26.
13.
Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. 2nd ed. New York: Wiley; 1999.
14.
Thompson LD, Heffess CS. Renal cell carcinoma to the pancreas in surgical pathology material. Cancer. 2000;89:1076–88.CrossRefPubMed
15.
Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, et al. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev. 2014;33:321–31.CrossRefPubMed
16.
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.CrossRefPubMed
17.
Santoni M, Conti A, Porta C, et al. Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5 years) metastatic renal cell carcinoma. J Urol. 2014. doi:10.​1016/​j.​juro.​2014.​07.​011.
18.
Machado NO, Chopra P. Pancreatic metastasis from renal carcinoma managed by Whipple resection: a case report and literature review of metastatic pattern, surgical management and outcome. JOP 2009;10:413–8.PubMed
19.
Eidt S, Jergas M, Schmidt R, Siedek M. Metastasis to the pancreas: an indication for pancreatic resection? Langenbecks Arch Surg. 2007;392:539–42.CrossRefPubMed
20.
Zerbi A, Ortolano E, Balzano G, Borri A, Beneduce AA, Di Carlo V. Pancreatic metastasis from renal cell carcinoma: which patients benefit from surgical resection? Ann Surg Oncol. 2008;15:1161–8.CrossRefPubMed
21.
Yazbek T, Gayet B. The place of enucleation and enucleo-resection in the treatment of pancreatic metastasis of renal cell carcinoma. JOP. 2012;13(4):433–8.PubMed
22.
Niess H, Conrad C, Kleespies A, et al. Surgery for metastasis to the pancreas: is it safe and effective? J Surg Oncol. 2013;107:859–64.CrossRefPubMed
23.
Adler H, Redmond CE, Heneghan HM, Swan N, Maguire D, Traynor O, et al. Pancreatectomy for metastatic disease: a systematic review. Eur J Surg Oncol. 2014;40:379–86.CrossRefPubMed
Metadata
Title
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors
Authors
Matteo Santoni, MD
Alessandro Conti, MD
Stefano Partelli, MD
Camillo Porta, MD
Cora N. Sternberg, MD, PhD
Giuseppe Procopio, MD
Sergio Bracarda, MD
Umberto Basso, MD
Ugo De Giorgi, MD
Lisa Derosa, MD
Mimma Rizzo, MD
Cinzia Ortega, MD
Francesco Massari, MD
Roberto Iacovelli, MD
Michele Milella, MD
Giuseppe Di Lorenzo, MD
Sebastiano Buti, MD
Linda Cerbone, MD
Luciano Burattini, MD
Rodolfo Montironi, MD, PhD
Daniele Santini, MD, PhD
Massimo Falconi, MD, PhD
Stefano Cascinu, MD, PhD
Publication date
01-06-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 6/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4256-7

Other articles of this Issue 6/2015

Annals of Surgical Oncology 6/2015 Go to the issue

Endocrine Tumors

Thyroid Cancer Presentation and Treatment in the United States

Colorectal Cancer

Radical Surgery with Total Mesorectal Excision in Patients with T1 Rectal Cancer

Pancreatic Tumors

The Canary in the Coal Mine: The Growth of Patient-Derived Tumorgrafts in Mice Predicts Clinical Recurrence after Surgical Resection of Pancreatic Ductal Adenocarcinoma

Hepatobiliary Tumors

Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases

Breast Oncology

Increased Risk of Surgical Site Infection Among Breast-Conserving Surgery Re-excisions

Breast Oncology

Breast Cancer Screening at the Breast Examination Center of Harlem